AR017754A1 - Macrolidas cristalinas, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento - Google Patents

Macrolidas cristalinas, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento

Info

Publication number
AR017754A1
AR017754A1 ARP980103094A ARP980103094A AR017754A1 AR 017754 A1 AR017754 A1 AR 017754A1 AR P980103094 A ARP980103094 A AR P980103094A AR P980103094 A ARP980103094 A AR P980103094A AR 017754 A1 AR017754 A1 AR 017754A1
Authority
AR
Argentina
Prior art keywords
preparation
compound
formula
macrolidas
cristalinas
Prior art date
Application number
ARP980103094A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10815103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR017754(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR017754A1 publication Critical patent/AR017754A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Metallurgy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP980103094A 1997-06-30 1998-06-26 Macrolidas cristalinas, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento AR017754A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9713730.1A GB9713730D0 (en) 1997-06-30 1997-06-30 Organic compounds

Publications (1)

Publication Number Publication Date
AR017754A1 true AR017754A1 (es) 2001-10-24

Family

ID=10815103

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103094A AR017754A1 (es) 1997-06-30 1998-06-26 Macrolidas cristalinas, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento

Country Status (31)

Country Link
US (1) US6423722B1 (enExample)
EP (1) EP0994880B1 (enExample)
JP (2) JP3880634B2 (enExample)
KR (1) KR100399765B1 (enExample)
CN (1) CN1139595C (enExample)
AR (1) AR017754A1 (enExample)
AT (1) ATE287410T1 (enExample)
AU (1) AU739211B2 (enExample)
BR (1) BR9810956A (enExample)
CA (1) CA2290412C (enExample)
CO (1) CO4940463A1 (enExample)
CZ (1) CZ297244B6 (enExample)
DE (1) DE69828692T2 (enExample)
DK (1) DK0994880T3 (enExample)
ES (1) ES2236922T3 (enExample)
GB (1) GB9713730D0 (enExample)
HU (1) HU227755B1 (enExample)
ID (1) ID24897A (enExample)
IL (1) IL132761A0 (enExample)
MY (1) MY118718A (enExample)
NO (1) NO312765B1 (enExample)
NZ (1) NZ500994A (enExample)
PE (1) PE97699A1 (enExample)
PL (1) PL192761B1 (enExample)
PT (1) PT994880E (enExample)
RU (1) RU2219181C2 (enExample)
SK (1) SK285665B6 (enExample)
TR (1) TR199903189T2 (enExample)
TW (1) TW552264B (enExample)
WO (1) WO1999001458A1 (enExample)
ZA (1) ZA985655B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
US7875630B2 (en) * 2003-09-03 2011-01-25 Glaxo Group Limited Process salts compositions and use
AU2005230401B2 (en) * 2004-04-08 2008-11-27 Meda Pharma S.A.R.L. Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
TW200628483A (en) 2004-12-01 2006-08-16 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Processes for producing crystalline macrolides
EP1960406A2 (en) * 2006-11-06 2008-08-27 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
EP2099298A4 (en) * 2006-12-07 2010-01-06 Helsinn Healthcare Sa CRYSTALLINE AND AMORPHOUS FORMS OF PALONOSETRON HYDROCHLORIDE
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
EP2451496B1 (en) 2009-07-10 2015-07-22 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
WO2011008393A2 (en) 2009-07-17 2011-01-20 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8669360B2 (en) * 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
SG10202112135VA (en) 2013-03-15 2021-12-30 Biosensors International Group Ltd Purification of rapamycin derivatives
EP3178824A1 (en) 2015-12-08 2017-06-14 Medichem, S.A. Process for preparing pimecrolimus
WO2018202733A1 (en) * 2017-05-01 2018-11-08 Meda Pharma Gmbh & Co. Kg Process to convert crude ascomycin into purified pimecrolimus
EP3741367A1 (en) 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease
WO2024209038A1 (en) 2023-04-06 2024-10-10 Premark Pharma Gmbh Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
GB2084580B (en) 1980-10-01 1984-07-04 Glaxo Group Ltd Aminoalkyl furan derivative
JP2728482B2 (ja) * 1989-01-26 1998-03-18 協和醗酵工業株式会社 マクロライド系抗生物質の精製法
JPH089630B2 (ja) 1989-07-10 1996-01-31 ヘマ・ソシエダード・アノニマ 有機化合物の、または関連する改善
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
IE910847A1 (en) * 1990-03-13 1991-09-25 Fisons Plc Immunosuppressive macrocyclic compounds
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
EP0480623A1 (en) * 1990-10-11 1992-04-15 Merck & Co. Inc. New halomacrolides and derivatives having immunosuppressive activity
ES2100291T3 (es) 1991-07-30 1997-06-16 Ajinomoto Kk Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos.
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
JP3808500B2 (ja) * 1994-02-22 2006-08-09 キューレータズ オブ ディ ユニバーシティ オブ ミズーリ 分離剤としての大環状抗生物質
WO1997008182A1 (en) * 1995-08-24 1997-03-06 Merck & Co., Inc. Process for the preparation of imidazolyl macrolide immunosuppressants
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds

Also Published As

Publication number Publication date
EP0994880A1 (en) 2000-04-26
HUP0003053A3 (en) 2003-03-28
US6423722B1 (en) 2002-07-23
JP2006151999A (ja) 2006-06-15
CZ297244B6 (cs) 2006-10-11
GB9713730D0 (en) 1997-09-03
PE97699A1 (es) 1999-10-29
PL192761B1 (pl) 2006-12-29
RU2219181C2 (ru) 2003-12-20
ATE287410T1 (de) 2005-02-15
IL132761A0 (en) 2001-03-19
EP0994880B1 (en) 2005-01-19
ID24897A (id) 2000-08-31
PT994880E (pt) 2005-06-30
CN1261365A (zh) 2000-07-26
KR20010020423A (ko) 2001-03-15
AU739211B2 (en) 2001-10-04
CO4940463A1 (es) 2000-07-24
CA2290412A1 (en) 1999-01-14
ZA985655B (en) 1998-12-30
SK285665B6 (sk) 2007-05-03
HK1028597A1 (en) 2001-02-23
DE69828692D1 (de) 2005-02-24
CN1139595C (zh) 2004-02-25
BR9810956A (pt) 2000-09-26
JP3880634B2 (ja) 2007-02-14
JP2001506279A (ja) 2001-05-15
DK0994880T3 (da) 2005-05-30
SK186699A3 (en) 2000-05-16
CZ474099A3 (cs) 2000-04-12
JP4504323B2 (ja) 2010-07-14
TR199903189T2 (xx) 2000-06-21
NO312765B1 (no) 2002-07-01
AU8540998A (en) 1999-01-25
NZ500994A (en) 2001-08-31
PL336719A1 (en) 2000-07-03
WO1999001458A1 (en) 1999-01-14
KR100399765B1 (ko) 2003-09-29
NO995909D0 (no) 1999-12-02
ES2236922T3 (es) 2005-07-16
HU227755B1 (en) 2012-02-28
HUP0003053A2 (hu) 2001-02-28
TW552264B (en) 2003-09-11
MY118718A (en) 2005-01-31
DE69828692T2 (de) 2006-01-12
NO995909L (no) 1999-12-02
CA2290412C (en) 2009-11-10

Similar Documents

Publication Publication Date Title
AR017754A1 (es) Macrolidas cristalinas, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento
BR9915420A (pt) Composto, composição farmacêutica, métodos de tratar um distúrbio mediado por tnf e por p38 cinase, inflamação e artrite e processo de preparar pirazóis
CO5310550A1 (es) Nuevo derivado de androstano antiinflamatorio, su polimorfo, sus formas cristalinas solvatadas, composiciones farmaceutias, proceso para prepararlo, intermediario
BR9803179A (pt) Antagonistas receptores de ccr-3.
AR002705A1 (es) Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen.
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
GT198304062A (es) Derivado epimerico de azahomoeritromicina a e intermedios del mismo
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
CO5390079A1 (es) Compuestos heterociclicos novedosos que tienen actividades hipolipidemicas, hipocolesterolicas, proceso para su preparacion y composiciones farmaceuticas que los contienen y su uso en medicina
NO881933L (no) Orale administreringsformer med forsinket avgivning.
NO20022558L (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
AR029571A1 (es) Nueva forma cristalina beta de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
BR0008011A (pt) Agente embranquecedor fluorescente, suapreparação e uso
UY27410A1 (es) Formas novedosas crudas cristalinas
CL43546B (es) Compuesto derivado de tetrahidroquinolina con actividad moduladora del receptor fsh; composicion farmaceutica que contiene al compuesto; y uso del compuesto en la preparacion de medicamentos para la regulacion de la fertilidad.
BR0109508A (pt) Forma ii, cristalina, de cabergolina
PE79799A1 (es) Forma cristalina de 1-(2,6-difluorbencil)-1h-1,2,3-triazol-4-carboxamida
AR035553A1 (es) Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos.
ECSP982561A (es) Macrolidas cristalinas
BR9902347A (pt) Azabiciclos como inibidores de rotomase
EP0443957A3 (en) New 17-spiro substituted steroid compounds, process for their preparation and intermediates of this process, their use as medicines and pharmaceutical preparations containing them
ES2185666T3 (es) Formulacion estabilizada para comprimidos.
ECSP034533A (es) Derivados sustituyentes 5-amino-1 penteno-3-ol
ATE28647T1 (de) Chinazolinonderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
UY26251A1 (es) Forma cristalina iii de la n- (4-(5- dimetilaminonaftalen-1- sulfonilamino) fenil) -3 - hidroxi-2, 2- dimetilpropionamida

Legal Events

Date Code Title Description
FG Grant, registration